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of a QA programme and to feed back deviations to 
investigators.  
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Purpose/Objective: Continuous Positive Airway Pressure 
(CPAP) has long been used in patients with obstructive sleep 
apnea to maintain airway patency. There are no reports 
describing CPAP use with radiation therapy. We performed a 
prospective clinical trial to determine if CPAP reduces tumor 
motion, expands lung volume and improves dosimetric 
parameters in patients receiving lung SBRT. 
Materials and Methods: IRB approval was given in December 
2013. Inclusion criteria included adult patients with primary 
or secondary lung tumors referred for SBRT. Following 
informed consent and training, subjects underwent 4D 
simulation twice: without CPAP (free-breathing) and with 
CPAP. Treatment was planned using Eclipse (Varian). The ITV 
was expanded 5mm to create PTV. Volumetric and dosimetric 
parameters with and without CPAP were compared using 
Student's paired two-tailed t-test. CPAP was utilized during 
treatment if judged beneficial. Daily cone beam CT's were 
taken. 
Results: Twelve patients were enrolled, one subject 
withdrew due to mask discomfort, 11 were planned and 10 
were treated to 18 different lesions. Mean dose (Eq2GY): 85 
Gy (range: 32Gy-126Gy), One patient was treated with a 
SBRT boost and received 33Gy (Eq2Gy). CPAP increased mean 
lung volume by 26.4% (CI 95%, 20-32.8, p 
Conclusions: CPAP used during lung SBRT was safe, well 
tolerated, and provided clinical and dosimetric benefit in 
almost all patients. Compared to free breathing, CPAP 
increased total lung volume, decreased ITV and PTV, and 
reduced heart and lung dose. Clinical trials are in progress 
studying additional applications and optimal methods for use 
of this novel technique.  
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Purpose/Objective: Isotoxic IMRT is a multicentre feasibility 
study recruiting patients with stage III non small cell lung 
cancer, not suitable for concurrent chemo-radiotherapy. 
Patients recruited will be treated with individualised doses of 
radiation based on pre-specified normal tissue doses. 
Radiotherapy will be delivered twice-daily over a maximum 
period of 4.5 weeks using IMRT and the radiation dose will be 
increased until one or more of the OAR tolerance or the 
maximum dose of 79.2Gy is reached.  
As part of the quality assurance programme (QA) a 
comparison of the conformity of organ at risk (OAR) outlining 
and planning technique has been undertaken. 
Materials and Methods: Centres were asked to complete an 
outlining benchmark case (assessing OAR outlining) and a 
planning benchmark case (assessing treatment planning 
technique).  
The outlining results presented are from 5 centres (A to E) as 
the outlines from the sixth centre (F) were used as the gold 
standard (GS) outlines for the exercise. 
DICE similarity coefficient (DSC) was defined as 
(2 * UNION of Vol_GS and Vol_centre) / (Vol_GS + 
Vol_centre).  
DSC values range from 0 to 1, with1 denoting complete 
conformity to the gold standard and levels above 0.6 
considered good for this case. 
Results: Outlining benchmark case - Figure 1 shows DSC for 
centres A to E for the OAR outlining. 
Planning benchmark case- 4 out of the 6 centres were able to 
achieve the maximum dose/number of fractions. The most 
common limitation to dose escalation was dose to the 1cc 
mediastinal envelope.  
Figure 1 
 
 
Conclusions: Results show good conformity of OAR outlining 
from centres A-E compared to gold standard outlines, except 
for brachial plexus. PTV coverage for all centres was 
compliant with the limits set by the trial protocol. 
Pre-trial QA is an essential part of the trial QA process as it 
will reduce the risk of deviation from protocol.  
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